Evidence map›Paper›PMID 36114414›Full record

ReviewNature reviews. Nephrology2022

Epidemiology of peritoneal dialysis outcomes.

Aminu K Bello, Ikechi G Okpechi, Mohamed A Osman, Yeoungjee Cho, Brett Cullis, Htay Htay, Vivekanand Jha, Muhammad A Makusidi, Mignon McCulloch, Nikhil Shah and 2 more

3 registry-linked trialsOpen access · bronzeAbstract readReview
In one paragraph

Review in Nature reviews. Nephrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 141 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
141citing papers in PubMed, 3 pooled it
29.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06060951 unknown statusnot on this mapstarted 2023, after this paper: background citation

To Investigate the Relationship Between Estimated Intraperitoneal Pressure and Non-infectious Peritoneal Dialysis (PD)-Related Abdominal Complications

TypeobservationalSponsorImperial College Healthcare NHS TrustRan2023 to 2025Enrolled300ConditionsPeritoneal Dialysis, Kidney Failure, Chronic, Hernia, AbdominalArmsEstimated intraperitoneal pressure
NCT06398977 narecruitingnot on this mapstarted 2024, after this paper: background citation

Dapagliflozin Delays the Loss of Residual Renal Function in Patients Undergoing Peritoneal Dialysis: A Single-Center Randomized Open-Label Study

TypeinterventionalSponsorSichuan Academy of Medical SciencesRan2024 to 2026Enrolled70ConditionsPeritoneal Dialysis Complication, Renal Function Aggravated, Sodium-glucose Co-transporter-2 InhibitorsArmsDapagliflozin
NCT06842927 enrolling by invitationnot on this mapstarted 2025, after this paper: background citation

DETECT-PD -- Dialysis Efficiency and Transporter Evaluation Computational Tool in Peritoneal Dialysis

TypeobservationalSponsorTuen Mun HospitalRan2025 to 2026Enrolled350ConditionsEnd-Stage Kidney Disease, End Stage Renal Disease (ESRD), End Stage Renal Disease on Dialysis (Diagnosis), End Stage Renal Failure on DialysisArmsdata collection, data report
3 · Its place in the literature

Who cites it

141 citing papers in PubMed, 3 syntheses or guidelines pooled it, 218 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Sex-Specific Outcomes in the Peritoneal Dialysis Outcomes and Practice Patterns Study.Clinical journal of the American Society of Nephrology : CJASN · 2026
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

81 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 7 countries.

Aminu K BelloDepartment of Medicine, University of Alberta, Edmonton, Alberta, Canada.ORCID 0000-0002-6905-5937
Ikechi G OkpechiDepartment of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Mohamed A OsmanDepartment of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Yeoungjee ChoCentre for Kidney Disease Research, University of Queensland, Brisbane, Australia.
Brett CullisRenal Unit, Greys Hospital, Pietermaritzburg, South Africa.
Htay HtayDepartment of Renal Medicine, Singapore General Hospital, Singapore, Singapore.
Vivekanand JhaGeorge Institute for Global Health, UNSW, New Delhi, India.ORCID 0000-0002-8015-9470
Muhammad A MakusidiFaculty of Medicine, Usmanu Danfodiyo University, Sokoto, Nigeria.
Mignon McCullochRed Cross War Memorial Children's Hospital, University of Cape Town, Cape Town, South Africa.ORCID 0000-0003-2876-4785
Nikhil ShahDepartment of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Marina WainsteinCentre for Kidney Disease Research, University of Queensland, Brisbane, Australia.
David W JohnsonCentre for Kidney Disease Research, University of Queensland, Brisbane, Australia. david.johnson2@health.qld.gov.au.ORCID 0000-0001-5491-3460
University of Alberta · CAThe University of Queensland · AUUniversity of Cape Town · ZAManipal Academy of Higher Education · INSingapore General Hospital · SGUsmanu Danfodiyo University · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peritoneal dialysis (PD) is an important home-based treatment for kidney failure and accounts for 11% of all dialysis and 9% of all kidney replacement therapy globally. Although PD is available in 81% of countries, this provision ranges from 96% in high-income countries to 32% in low-income countries. Compared with haemodialysis, PD has numerous potential advantages, including a simpler technique, greater feasibility of use in remote communities, generally lower cost, lesser need for trained staff, fewer management challenges during natural disasters, possibly better survival in the first few years, greater ability to travel, fewer dietary restrictions, better preservation of residual kidney function, greater treatment satisfaction, better quality of life, better outcomes following subsequent kidney transplantation, delayed need for vascular access (especially in small children), reduced need for erythropoiesis-stimulating agents, and lower risk of blood-borne virus infections and of SARS-CoV-2 infection. PD outcomes have been improving over time but with great variability, driven by individual and system-level inequities and by centre effects; this variation is exacerbated by a lack of standardized outcome definitions. Potential strategies for outcome improvement include enhanced standardization, monitoring and reporting of PD outcomes, and the implementation of continuous quality improvement programmes and of PD-specific interventions, such as incremental PD, the use of biocompatible PD solutions and remote PD monitoring.

Indexed as

COVID-19Kidney Failure, ChronicPeritoneal DialysisChildHumansQuality of LifeRenal DialysisSARS-CoV-2

Identifiers

PMID36114414
PMCPMC9483482
OpenAlexW4296161657

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.